Context Therapeutics (CNTX) Return on Capital Employed (2021 - 2026)
Context Therapeutics (CNTX) posted Return on Capital Employed of 76.16% for Q1 2026, down 26.3% sequentially from 60.3% in Q4 2025, and down 4238.0% YoY from 1.84% in Q1 2025.
Context Therapeutics (CNTX) Return on Capital Employed (2021 - 2026) Analysis & Trends
Context Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 76.16% in Q1 2026.
- Quarterly Return on Capital Employed fell 4238.0% year-over-year to 76.16% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 76.16% (down 4238.0% YoY) and the FY2025 annual result came in at 52.73%, up 233.0% from the prior year.
- Return on Capital Employed retreated to 76.16% in Q1 2026 per CNTX's latest filing, from 60.3% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 27.6% in Q1 2022 and troughed at 203.03% in Q1 2024.
- A 5-year average of 64.78% and a median of 41.78% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 14440 bps in 2024, then jumped 16926 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 41.78% in 2022, then tumbled by 291 bps to 163.51% in 2023, then jumped by 80 bps to 33.44% in 2024, then plunged by 80 bps to 60.3% in 2025, then fell by 26 bps to 76.16% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 76.16%, 60.3%, and 39.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | -109.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -109.22% |
| Mar 31, 2026 | -76.16% |
| Dec 31, 2025 | -60.30% |
| Sep 30, 2025 | -39.15% |
| Jun 30, 2025 | -44.79% |
| Mar 31, 2025 | -33.78% |
| Dec 31, 2024 | -33.44% |
| Sep 30, 2024 | -35.30% |
| Jun 30, 2024 | -36.23% |
| Mar 31, 2024 | -203.03% |
| Dec 31, 2023 | -163.51% |
| Sep 30, 2023 | -106.02% |
| Jun 30, 2023 | -76.18% |
| Mar 31, 2023 | -58.63% |
| Dec 31, 2022 | -41.78% |
| Sep 30, 2022 | -37.05% |
| Jun 30, 2022 | -28.28% |
| Mar 31, 2022 | -27.60% |
| Dec 31, 2021 | -44.32% |